
P. Leia Nghiemphu, MD, discusses how the NCCN guideline inclusion of brigatinib expands treatment access for patients with NF2-related schwannomatosis.

P. Leia Nghiemphu, MD, is a professor of clinical neurology, director of the Neuro-Oncology Clinical Service, and clinical director of the UCLA Neurofibromatosis Program at UCLA Health

P. Leia Nghiemphu, MD, discusses how the NCCN guideline inclusion of brigatinib expands treatment access for patients with NF2-related schwannomatosis.